当前位置: 首页 >> 检索结果
共有 6658 条符合本次的查询结果, 用时 3.8672805 秒

1481. The Challenge of Diagnosing COPD in Individuals Who Have Never Smoked.

作者: Carlota Rodríguez-García.;Cristina Candal-Pedreira.;Mónica Pérez-Ríos.;Alberto Ruano-Ravina.;Luis Valdés-Cuadrado.
来源: Chest. 2023年164卷4期835-836页

1482. Are We Ready for Asthma Remission as a Clinical Outcome?

作者: Njira L Lugogo.;Arjun Mohan.;Praveen Akuthota.;Simon Couillard.;Sarah Rhoads.;Michael E Wechsler.
来源: Chest. 2023年164卷4期831-834页

1483. Cost Utility Analysis of Primary Spontaneous Pneumothorax Management: Another Reason to Choose Outpatient Options?

作者: Rob J Hallifax.
来源: Chest. 2023年164卷4期829-830页

1484. Breaking a Sweat to Catch Your Breath: Exercise Therapy Improves Dyspnea After Acute Pulmonary Embolism.

作者: Alexander E Sullivan.;Evan L Brittain.
来源: Chest. 2023年164卷4期826-828页

1485. Instilling Diversity, Equity, and Inclusion in the CHEST Journal Community.

作者: Laura Riordan.;Stephanie M Levine.; .
来源: Chest. 2023年164卷4期822-825页

1486. Simulation-Based Training in Flexible Bronchoscopy: Best Practices and Future Directions.

作者: Kristoffer Mazanti Cold.;Lars Konge.
来源: Chest. 2023年164卷4期820-821页

1487. Genetic and Lifestyle Risk Factors for Idiopathic Pulmonary Fibrosis: Greater Than the Sum of Its Parts.

作者: Chad A Newton.
来源: Chest. 2023年164卷4期818-819页

1488. The Emulated Targeted Trial: A Causal, But Never Casual, Surrogate for Randomized Clinical Trials.

作者: Pedro D Wendel-Garcia.;Lieuwe D J Bos.
来源: Chest. 2023年164卷4期816-817页

1489. Lung-Protective Concept and Noninvasive Respiratory Support.

作者: Masaaki Sakuraya.
来源: Chest. 2023年164卷4期814-815页

1490. Fluid Therapy in Sepsis: Does It Matter How Much?

作者: Jonathan A Silversides.;Bram Rochwerg.
来源: Chest. 2023年164卷4期812-813页

1491. Inhaled Corticosteroids in COPD and Bronchiectasis: Use Biomarkers Rather Than Disease Labels.

作者: James D Chalmers.;Amelia Shoemark.
来源: Chest. 2023年164卷4期809-811页

1492. Dornase Alfa and Hypertonic Saline: Pass the Salt?

作者: Marc A Sala.;Manu Jain.
来源: Chest. 2023年164卷4期807-808页

1493. Do-Not-Resuscitate Orders by COVID-19 Status Throughout the First Year of the COVID-19 Pandemic.

作者: Gina M Piscitello.;William F Parker.
来源: Chest. 2024年165卷3期601-609页
At the beginning of the COVID-19 pandemic, whether performing CPR on patients with COVID-19 would be effective or increase COVID-19 transmission to health care workers was unclear.

1494. Modification of Endotypic Traits in OSA by the Carbonic Anhydrase Inhibitor Sulthiame.

作者: Erik Hoff.;Christian Strassberger.;Ding Zou.;Ludger Grote.;Kaj Stenlöf.;Jan Hedner.
来源: Chest. 2024年165卷3期704-715页
The carbonic anhydrase inhibitor sulthiame reduces OSA severity, increases overnight oxygenation, and improves sleep quality. Insights into how sulthiame modulates OSA pathophysiologic features (endotypic traits) adds to our understanding of the breathing disorder itself, as well as the effects of carbonic anhydrases in respiratory regulation.

1495. Low Tidal Volume Ventilation Is Poorly Implemented for Patients in North American and United Kingdom ICUs Using Electronic Health Records.

作者: Romit J Samanta.;Ari Ercole.;Steven Harris.;Charlotte Summers.
来源: Chest. 2024年165卷2期333-347页
Low tidal volume ventilation (LTVV; < 8 mL/kg predicted body weight [PBW]) is a well-established standard of care associated with improved outcomes. This study used data collated in multicenter electronic health record ICU databases from the United Kingdom and the United States to analyze the use of LTVV in routine clinical practice.

1496. Using Trajectories of Bedside Vital Signs to Identify COVID-19 Subphenotypes.

作者: Sivasubramanium V Bhavani.;Chad Robichaux.;Philip A Verhoef.;Matthew M Churpek.;Craig M Coopersmith.
来源: Chest. 2024年165卷3期529-539页
Trajectories of bedside vital signs have been used to identify sepsis subphenotypes with distinct outcomes and treatment responses. The objective of this study was to validate the vitals trajectory model in a multicenter cohort of patients hospitalized with COVID-19 and to evaluate the clinical characteristics and outcomes of the resulting subphenotypes.

1497. Prevalence, Risk Factors, Clinical Features, and Outcome of Influenza-Associated Pulmonary Aspergillosis in Critically Ill Patients: A Systematic Review and Meta-Analysis.

作者: Lawrence Y Lu.;Hui Min Lee.;Andrew Burke.;Gianluigi Li Bassi.;Antoni Torres.;John F Fraser.;Jonathon P Fanning.
来源: Chest. 2024年165卷3期540-558页
Influenza-associated pulmonary aspergillosis (IAPA) increasingly is being reported in critically ill patients. We conducted this systematic review and meta-analysis to examine the prevalence, risk factors, clinical features, and outcomes of IAPA.

1498. Discrimination Predicts Suboptimal Adherence to CPAP Treatment and Mediates Black-White Differences in Use.

作者: Douglas M Wallace.;Andrea Barnes Grant.;Zuzana Belisova-Gyure.;Matthew Ebben.;Omonigho M Bubu.;Dayna A Johnson.;Girardin Jean-Louis.;Natasha J Williams.
来源: Chest. 2024年165卷2期437-445页
Although racial and ethnic differences in CPAP adherence for OSA are widely established, no studies have examined the influence of perceived racial discrimination on CPAP usage, to our knowledge.

1499. Effects of Sirolimus on Anti-SARS-CoV-2 Vaccination in Patients With Lymphangioleiomyomatosis.

作者: Tat'Yana Worthy.;Amanda Jones.;Bennett E Yang.;Hiroko Ishiwata-Endo.;Nishant Gupta.;Joel Moss.
来源: Chest. 2024年165卷2期303-306页

1500. Accuracy of Cytologic vs Histologic Specimens for Assessment of Programmed Cell Death Ligand-1 Expression in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

作者: Pattraporn Tajarernmuang.;Felipe Aliaga.;Amr J Alwakeel.;Gamuchirai Tavaziva.;Kimberly Turner.;Dick Menzies.;Hangjun Wang.;Linda Ofiara.;Andrea Benedetti.;Anne V Gonzalez.
来源: Chest. 2024年165卷2期461-474页
Programmed cell death ligand-1 (PD-L1) expression on tumor cells, evaluated by immunohistochemistry, guides the use of immunotherapy in advanced non-small cell lung cancer (NSCLC).
共有 6658 条符合本次的查询结果, 用时 3.8672805 秒